Recent Commentaries tagged (ilmn)
Genomic Misses, Grows Annually - Analyst Blog
Genomic Health (GHDX) reported an EPS of 8 cents in the fourth quarter of fiscal 2011, a penny below the Zacks Consensus Estimate, but higher than 6 cents earned in the year-ago period. For the full year, EPS came in at 26 cents, missing the Zacks Consensus Estimate of 27 cents and way above 14 c...
Read More »
Tags: analyst-blog | ghdx | ilmn | life | rhhby | stocks
Earnings Preview: Life Technologies -...
Global biotechnology company, Life Technologies (LIFE) is scheduled to report its fourth quarter and fiscal 2011 results on Tuesday, February 7, 2012, after market close. The company is expected to earn EPS of $1.03 on revenues of $965 million during the quarter and $3.70 on revenues of $3,734 m...
Read More »
Tags: analyst-blog | ilmn | life | rhhby
Roche Beats; Optimistic about 2012 - Analyst...
Roche Holdings Ltd.'s (RHHBY) fiscal 2011 earnings per share came in at $3.48, compared with $3.07 reported in the year-ago period. Earnings came in ahead of the Zacks Consensus Estimate of $3.31. Earnings were helped by reduced financial expenses and a lower tax rate. Revenues declined 10% (in S...
Read More »
Tags: analyst-blog | ilmn | rhhby | stocks
Roche Aims for Illumina - Analyst Blog
Roche Holdings Ltd. (RHHBY) recently announced that it has placed a bid to acquire all the outstanding shares of Illumina Inc. (ILMN). Roche's offer of $44.50 per share (aggregate value $5.7 billion) in cash represents a 64% premium over Illumina's stock price on December 21, 2011. On December ...
Read More »
Tags: analyst-blog | ilmn | rhhby
